Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.

J Comp Eff Res 2018 02 15;7(2):121-133. Epub 2017 Aug 15.

Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, USA.

Aim: Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA).

Materials & Methods: Data from six Medicaid states (07/2009-03/2015) were used to compare outcomes between PP1M and OAA patients.

Results: PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients. PP1M patients had lower medical (mean monthly cost difference [MMCD] = US$-191, p = 0.020), higher pharmacy (MMCD = US$250, p < 0.001) and similar total costs (MMCD = US$59, p = 0.517) during the overall follow-up. PP1M patients had lower rates of outpatient visits and inpatient days but higher rates of mental health-related utilization.

Conclusion: PP1M was associated with higher antipsychotic adherence and persistence, and similar total costs versus OAA.

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2017-0043DOI Listing
February 2018
52 Reads

Publication Analysis

Top Keywords

schizophrenia patients
8
oral atypical
8
patients substance-related
8
substance-related disorders
8
pp1m patients
8
paliperidone palmitate
8
patients
5
compare outcomes
4
07/2009-03/2015 compare
4
states 07/2009-03/2015
4
outcomes pp1m
4
pp1m oaa
4
us$250 p 
4
patientsresults pp1m
4
oaa patientsresults
4
medicaid states
4
data medicaid
4
pp1m
4
once-monthly paliperidone
4
initiated once-monthly
4

References

(Supplied by CrossRef)

Winklbaur B et al.
Dialogues Clin. Neurosci. 2006

Similar Publications